All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-12-11T17:45:40.000Z

ASH 2018 | CAR T cell clinical trial for patients with relapsed/refractory multiple myeloma using bb21217

Dec 11, 2018
Share:

Bookmark this article

The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. On Sunday 2 December 2018, an oral abstract session was held entitled: Gene Therapy and Transfer: Clinical Trials for Hemophilia and Using CAR T Cells Hematology Disease Topics & Pathway. During that session, Nina Shah from UCSF, San Francisco, US, presented results of the CRB-402, a non-randomized phase I clinical trial that uses chimeric antigen receptor (CAR) T cell therapy to target the plasma cell surface molecule BCMA (B-cell maturation antigen).

In this trial, CAR T cells were engineered carrying the bb21217 construct. This next-generation anti-BCMA target has the same design as bb2121. However, bb21217 transduced T cells are cultured in medium with the phosphoinositide 3 (PI3) kinase inhibitor bb007, which significantly increases the percentage of CD27+ and CD62L+ T cells. These T-cell markers seem to be found predominantly on the surface of memory T cells. Pre-clinical studies suggest that memory T cells could have a longer lifespan than other T cell types and enhance the duration of response to CAR T cell therapy.

CRB-402 is the first clinical trial using bb21217 in patients with relapsed/refractory (R/R) multiple myeloma (MM). The primary outcome measures are the incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs). Secondary endpoints are disease-specific response criteria, including complete response (CR), very good partial response (VGPR), and minimal residual disease (MRD) among others.

Study Design:

  • Number of R/R MM patients = ~ 50
  • Prior treatments: At least three, including a proteasome inhibitor and an immunomodulatory agent, or double refractory patients
  • Dose escalation: Restricted to patients with ≥ 50% BCMA expression, defined by immunohistochemistry on plasma cells
  • T cells are extracted from patients with leukapheresis and sent to a central facility for viral transduction with the bb21217 construct, expansion, and testing prior to infusion
  • Five days before infusion: Patients undergo lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2), daily for three days (days -5, -4, -3)
  • On the day of infusion (day 1): Single infusion of bb21217
  • Clinical trial design: 3 + 3 dose escalation
  • Planned dose levels: 150, 350, 450, and 800 x 106 CAR T cells
  • Patients characterized as high tumor burden (HTB) or low tumor burden (LTB) (≥ 50% or < 50% bone marrow [BM] cells per infusion, respectively)

Key Data:

  • Data cut-off = 18 October 2018
  • Median age = 63 (range, 44–69)
  • Gender = 6 male; 6 female
  • Collected samples = 13
  • Dosed samples = 12; dose = 150 x 106 CAR T cells; HTB = 6 samples; LTB = 6 samples
  • Median follow-up = 26 weeks (range, 4–51)
  • ECOG performance status: 0 = 3 patients; 1 = 9 patients
  • International Staging System (ISS) stage: I = 1 patient; II = 2 patients; III = 4 patients
  • Patients with high-risk cytogenetics: n = 7
  • Median number of prior regimens = 7 (range, 4–17)
  • Patients with prior autologous stem cell transplant (ASCT): n = 10/12
  • Prior treatments: 11/12 patients had previously received lenalidomide and bortezomib and 7/11 were refractory to these drugs
  • Patients who developed cytokine release syndrome (CRS): n = 8/12; grade 1, n = 4; grade 2, n = 3; grade 3, n = 1; grade 4, n = 0; CRS was managed with or without tocilizumab
  • Median time to onset of CRS = 4.5 days (range, 2–11)
  • Patients who developed CAR T neurotoxicity, occurring within 90 days after infusion: n = 3/12
    • One patient with HTB and rapidly accelerating disease experienced DLT (grade 3 CRS and grade 4 encephalopathy)
    • After this event, patients were divided into HTB and LTB groups
    • No other DLTs occurred
  • Adverse events (AEs) (grade ≥ 3):
    • Neutropenia: grade 3, 8%; grade 4, 75%
    • Thrombocytopenia: grade 3, 25%; grade 4, 25%
    • Anemia: grade 3, 42%
    • Leukopenia: grade 3, 17%; grade 4, 25%
    • Lymphopenia: grade 3, 8%; grade 4, 17%
    • Hypophosphatemia: grade 3, 17%
  • Patients who experienced serious AEs: n = 4 (one or more serious AE)
  • Severe infections: n = 1, grade 3 catheter-related infection
  • No deaths up to the cut-off date
  • Recovery from grade 3/4 cytopenias:
    • Neutropenia: 11/12 patients had absolute neutrophil count ≥ 1,000/μl by day 65 post-infusion
    • Thrombocytopenia: 10/12 patients had platelet count ≥ 50,000/μl by day 65 post-infusion
  • Clinical responses:
    • Objective response rate (ORR) = 10/12 patients (95% confidence interval [CI], 51.6–97.9)
    • Stringent CR (sCR)/CR = 3 patients
    • VGPR or better (≥ VGPR) = 6 patients
    • Median time to first response = 1 month (range, 1–2)
    • Median time to best response = 1 month (range, 1–10)
    • Response ongoing in all but one responder; the first patient dosed continues to respond more than a year after treatment
    • MRD: 4/4 responders evaluable for MRD status were MRD negative; 2/2 non-responders were MRD positive
  • BM response:
    • BM plasma cell clearance observed by day 15 post-infusion
    • A substantial decline in free light chains in all responders within one month post-infusion
    • Sustained serum BCMA suppression observed up to nine months post-infusion
  • Robust expansion of infused CAR+ T cells enriched for memory-like T cells
  • Detectable CAR+ T cells up to nine months post-infusion

Conclusions

The initial results of this CAR T trial for R/R MM patients show efficacy of bb21217 at a dose of 150 x 106 CAR+ T cells. Participants showed 83% ORR with ongoing responses up to 90%. The safety profile appears consistent with known toxicities of CAR T cell therapies. The dose escalation is ongoing. A longer follow-up in a larger patient population will expand the data regarding the depth and durability of bb21217 tumor responses and dose response.

References

Shah N. et al. Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. 2018 Dec 2; Oral Abstract #488: ASH 60th Annual Meeting and Exposition, San Diego, CA.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox